Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will ...
The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer Pivotal results from the Phase 3 portion with mFOLFOX6 of the ...
The FDA has granted traditional approval to encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, Eli Lilly) and fluorouracil-based chemotherapy for treatment of adults with ...
Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse ...
Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...
Finding new ways in the approach to colorectal cancer is therefore fundamental. And there is no shortage of good news. Italy is the first country in Europe to guarantee, through the National Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results